Eric Joseph
Stock Analyst at JP Morgan
(1.25)
# 3,640
Out of 4,969 analysts
126
Total ratings
34.88%
Success rate
-12.01%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $43.32 | +47.74% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.35 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.32 | +1,225.30% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $7.40 | -5.41% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $55.60 | +20.50% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.38 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.72 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $9.42 | +218.47% | 7 | Jan 29, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $5.52 | +153.67% | 5 | Jan 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $63 → $71 | $39.80 | +78.41% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $31.71 | +35.60% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $14.04 | +170.66% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.41 | +1,531.21% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.99 | +112.77% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $4.11 | +410.95% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $18.76 | +155.86% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $8.84 | +13.12% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.10 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.92 | +681.25% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.58 | +133.01% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $4.63 | +115.98% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $5.02 | +119.34% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $45.63 | -10.15% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $11.46 | +772.60% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.47 | +967.92% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.46 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $7.45 | +47.65% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $12.50 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $7.03 | +1,606.97% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $10.64 | +2,719.55% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.18 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.44 | +527.18% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.12 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.88 | +1,358.33% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.23 | +956.91% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.53 | +1,958.77% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $43.32
Upside: +47.74%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.35
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.32
Upside: +1,225.30%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $7.40
Upside: -5.41%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $55.60
Upside: +20.50%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.38
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.72
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $9.42
Upside: +218.47%
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $5.52
Upside: +153.67%
Revolution Medicines
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $39.80
Upside: +78.41%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $31.71
Upside: +35.60%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $14.04
Upside: +170.66%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.41
Upside: +1,531.21%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.99
Upside: +112.77%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $4.11
Upside: +410.95%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $18.76
Upside: +155.86%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $8.84
Upside: +13.12%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.10
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.92
Upside: +681.25%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.58
Upside: +133.01%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $4.63
Upside: +115.98%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $5.02
Upside: +119.34%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $45.63
Upside: -10.15%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $11.46
Upside: +772.60%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.47
Upside: +967.92%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.46
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.45
Upside: +47.65%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $12.50
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $7.03
Upside: +1,606.97%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $10.64
Upside: +2,719.55%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.18
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.44
Upside: +527.18%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.12
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.88
Upside: +1,358.33%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.23
Upside: +956.91%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.53
Upside: +1,958.77%